Media Centre

August 7th 2018

From pharma to diagnostics: how Rhythm Biosciences found its new COO

Glenn Gilbert started out “literally pushing eggs around in a trolley” at biotech giant CSL in 2004 — and has risen through the ranks to become COO at bowel cancer tech startup Rhythm Biosciences. That was the same year Rhythm Biosciences (ASX:RHY) launched its flagship technology: inexpensive blood tests that can identify patients at high risk of having colon cancer. Read more
 

July 19th 2018

Rhythm Biosciences’ ColoSTAT recognised in global markets

Having been granted patents in Australia, ColoSTAT, the antibody-based blood test targeting the accurate and early detection of colorectal cancer was subsequently granted a European patent. This covers 13 jurisdictions including large markets such as the United Kingdom, France and Germany, as well as countries in the Nordic, northern European and Eastern European regions. The company has patents pending in the US, Brazil and India, and a divisional patent application pending in China. Read more
 

June 15th 2018

Merchant Group increases stake in Rhythm Biosciences

Medical diagnostics small cap Rhythm Biosciences Limited (ASX:RHY) has today announced that its new shareholder Merchant Group has increased its equity stake in the company from 5.02% to 7.01%. This follows the announcement earlier this week detailing the news of Merchant’s substantial investment in the company. At the time RHY CEO Dr Trevor Lockett referred to Merchant as “a supportive equity partner” with an “enviable record of combining thorough research with exceptional returns”. Read more

 

June 12th 2018

Rhythm Biosciences scores leading biotech fund as new shareholder

Medical diagnostics innovator, Rhythm Biosciences (ASX:RHY), has welcomed leading biotech investor, Merchant Group, as a major new shareholder. The Merchant Opportunities Fund, which now holds 5.02 per cent of RHY, has long been recognised as a successful, long-term investor in biotech companies that are nearing commercialisation. Read more

1 2 3 4 5 6